Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。